HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. (Q44922052)

7 December 2017

HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. (English)

1 reference

7 December 2017

Huiping Zhou

1

1 reference

7 December 2017

Emily C Gurley

2

1 reference

7 December 2017

Sirikalaya Jarujaron

3

1 reference

7 December 2017

Hong Ding

4

1 reference

7 December 2017

Youwen Fang

5

1 reference

7 December 2017

Zhumei Xu

6

1 reference

7 December 2017

William M Pandak

7

1 reference

7 December 2017

Phillip B Hylemon

8

1 reference

7 December 2017

language of work or name

1 reference

20 July 2006

1 reference

American Journal of Physiology - Gastrointestinal and Liver Physiology

7 December 2017

1 reference

7 December 2017

291

1 reference

7 December 2017

G1071-80

1 reference

7 December 2017

6

1 reference

Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

7 December 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Degradation of endogenous hepatic heme by pathways not yielding carbon monoxide. Studies in normal rat liver and in primary hepatocyte culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Regulation of apoptosis by endoplasmic reticulum pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

HIV protease inhibitor-related lipodystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

HIV protease inhibitor ritonavir increases endothelial monolayer permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Impact of Various Antiretroviral Drugs and Their Plasma Concentrations on Plasma Lipids in Heavily Pretreated HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

SREBP transcription factors: master regulators of lipid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

21 January 2018

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Review of atazanavir: a novel HIV protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Atazanavir: new option for treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Coupling endoplasmic reticulum stress to the cell death program

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

The SREBP pathway--insights from Insigs and insects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Strategies for management and treatment of dyslipidemia in HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

How an inhibitor of the HIV-I protease modulates proteasome activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes by increasing levels of activated sterol regulatory element-binding proteins and decreasing cholesterol 7alpha-hydroxylase mRNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

21 January 2018

Update on HAART in HIV.

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

Signaling the unfolded protein response from the endoplasmic reticulum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPGI.00182.2006

21 January 2018

Identifiers

DOI

10.1152/AJPGI.00182.2006

1 reference

7 December 2017

1 reference